Results 131 to 140 of about 30,982 (215)

Post hoc analysis: 6 Months immunogenicity after third dose of BNT162b2 vs JNJ-78436735 After Two Doses of BNT162b2 vaccine in Solid Organ Transplant Recipients

In Solid Organ Transplant (SOT) recipients, due to immunosuppression, the immunogenicity after COVID-19 vaccination is suboptimal and its durability is unknown.
Arosemena, Leopoldo, Burke, George William, Simkins, Jacques, Vianna, Rodrigo M, Guerra, Giselle, Pallikkuth, Suresh, Martin, Eric, Munagala, Mrudula R, Sota, Katherine, Chen, Jessie, Manickavel, Suresh, Bini, Julia, Natori, Yoichiro, Mattiazzi, Adela, Anjan, Shweta   +14 more
core   +1 more source

BNT162b2 Covid-19 Vaccine in Adolescents

New England Journal of Medicine, 2021
openaire   +2 more sources

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar

New England Journal of Medicine, 2022
Laith J. Abu-Raddad, Hiam Chemaitelly, Roberto Bertollini   +2 more
openaire   +2 more sources

A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting

Scientific Reports
This 22-month cohort study investigated the durability and dynamics of humoral immune responses in 327 Malaysians vaccinated with either CoronaVac or BNT162b2 in early 2021, monitored up to 52 weeks following a BNT162b2 booster. Using the ImmuSAFE™ COVID 
Aini Syahida Mat Yassim, Anis Atifah Mohd Hisham, Nik Nur Atiqah Nik Daud, Nur Diana Anuar, Ti-Myen Tan, Rapeah Suppian, Mat Jusoh Siti Asmaa, Amiratul Aifa Mohamad Asri, Maryam Azlan, Nur Suhaila Idris, Rosediani Muhamad, Mohd Nor Norazmi   +11 more
doaj   +1 more source

Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study

Background: The evidence of SARS-CoV-2 vaccine effectiveness in people living with HIV (PLWH) is limited. This study evaluated the humoral immune response to CoronaVac™ (virus inactivated) and BNT162b2 (mRNA- based) vaccines in PLWH and HIV-negative ...
Vial Cox, María Cecilia, Silva, Macarena, Canals, Andrea, Hormazabal, Juan, Cortes Salinas, Lina Jimena, Charpentier, Paulo, Wolff, Marcelo   +6 more
core   +1 more source

Neurovascular Adverse Effects of Sars-Cov-2 Vaccination

Drug Design, Development and Therapy
Leonidas D Panos,1,2 Panagiotis Bargiotas,2 Georgios Hadjigeorgiou,2 Georgios D Panos3,4 1Department of Neurology, Bern University Hospital « Inselspital », Bern, Switzerland; 2Department of Neurology, School of Medicine, University of Cyprus, Nicosia ...
Panos LD, Bargiotas P, Hadjigeorgiou G, Panos GD   +3 more
doaj  

Antispike IgG antibody decay after immunisation with fractional versus full booster doses of COVID-19 vaccines: a 6-month longitudinal analysis of the FRACT-COV trial in Brazil

BMJ Public Health
Objectives To compare antispike IgG levels over a period of 182 days of follow-up in healthy adults who received full or fractional booster doses of BNT162b2 or AZD1222 after completing a primary series of Sinovac, BNT162b2 or AZD1222.Design Double-blind,
Haley Hedlin, Vivek Charu, Di Lu, Patricia Vieira da Silva, Julio Croda, Amy Zhang, Farah Qamar, Joelle I Rosser, Juliana Barros Verruck, Marco Antonio Moreira Puga, Roberto Dias de Oliveira, Victor Ritter, Blake Shaw, Jessica Couvillion Seidman, Alice Scott Carter, Stephen Luby, Denise Garrett   +16 more
doaj   +1 more source

BNT162b2 Vaccine Booster and Covid-19 Mortality

New England Journal of Medicine, 2022
openaire   +3 more sources

Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants

Summary CombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a
Ascaso del Río, Ana, Pérez Ingidua, Carla, García Pérez, Javier, Portolés Pérez, Antonio, Lora Pablos, David, Díez Fuertes, Francisco, Gómez De La Cámara, Agustín Ramón   +6 more
core   +1 more source

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

New England Journal of Medicine, 2021
Skowronski, Danuta M., Serres, Gaston De, Vergnes, Jean-Noel   +2 more
openaire   +5 more sources